# BLISS GVS PHARMA LTD.



23rd May, 2018

To,
The Secretary,
The Bombay Stock Exchange,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

SUBJECT: <u>Advertisement of Audited Financial Results for the Quarter and Financial</u>
Year ended 31st March 2018 in the Newspapers

BSE CODE: 506197

Dear Sir / Madam,

Pursuant to the provisions of Regulation 47(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the enclosed, extract copies of the Standalone and Consolidated Audited Financial Results of the Company for the quarter and Financial Year ended 31st March 2018 published in the following Newspapers dated 19/05/2018:

- 1) Economic Times
- 2) Maharashtra Times
- 3) Navshakti
- 4) Free Press Journal

Kindly acknowledged and take on record the same.

VS P

Thanking You,

For BLISS GVS PHARMA LIMITED

CHIEF FINANCIAL OFFICER

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory: Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404. Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com





## **BLISS GVS PHARMA LIMITED**

CIN No.- L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

### STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2018

Total Income ₹ 84167.50

PBT ₹ 14529.18

EBITDA ₹ 18947.59 22.51%

**EPS** ₹ 5.70

(₹ in Lakh

Particulars	Actual Management of the Control of	CONSOLIDATED			CONSOLIDATED	
	QUARTER ENDED 31.03.2018 (AUDITED)	QUARTER ENDED 31.12.2017 (UN-AUDITED)	QUARTER ENDED 31.03.2017 (AUDITED)	YEAR ENDED 31.03.2018 (AUDITED)	YEAR ENDED 31.03.2017 (AUDITED)	
Total income from operations (net)	16,710.04	19,592.25	25,838.09	81,514.00	80,235.11	
Net Profit / (Loss) from ordinary activities after tax	1,988.33	1,792.07	3,312.35	9,298.41	8,204.70	
Net Profit / (Loss) from ordinary activities after tax, exceptional and extraordinary items	-1,431.55	1,792.07	3,312.35	5,878.53	8,204.70	
Total Comprehensive Income for the period	-1,437.55	1,359.91	1,708.24	5,748.68	7,283.97	
Equity Share Capital	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	
Other Equity	some & cost : norm . P		Total Topoga L.	52,592.46	47,630.58	
Earnings Per Share	-1.39	1.74	3.21	5.70	7.95	
Basic and Diluted (in Rs.)	n des l'entities e					

#### Note:

- (1) The above is an extract of the detailed format of the Consolidated financial results for the Quarter and Year ended March 31, 2018 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015."
- (2) The full format of the Standalone and Consolidated financial results for the Quarter and Year ended March 31, 2018 are available on the Stock Exchange websites- www.bseindia.com and www.nseindia.com and on the Company's website www.blissgvs.com.
- (3) The results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act read with relevant rules issued there under.
- (4) The Board of Directors in their meeting held on May 17, 2018 has recommended dividend of ₹ 1/- per equity share i.e., 100% for the financial year 2017-18 which is subject to approval of shareholders in Annual General Meeting.

For and on behalf of the Board of Directors SD/-

S. N. KAMATH MANAGING DIRECTOR

Place : Mumbai Date : 17th May'2018



## BLISS GVS PHARMA LIMITE

CIN No.- L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

#### STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2018

Total Income ₹ 84167.50

PBT ₹ 14529.18 17.26% EBITDA ₹ 18947.59 22.51%

**EPS** ₹ 5.70

(₹ in Lakhs)

Particulars	CONSOLIDATED			CONSOLIDATED	
	QUARTER ENDED 31.03.2018 (AUDITED)	QUARTER ENDED 31.12.2017 (UN-AUDITED)	QUARTER ENDED 31.03.2017 (AUDITED)	YEAR ENDED 31.03.2018 (AUDITED)	YEAR ENDED 31.03.2017 (AUDITED)
Total income from operations (net)	16,710.04	19,592.25	25,838.09	81,514.00	80,235.11
Net Profit / (Loss) from ordinary activities after tax	1,988.33	1,792.07	3,312.35	9,298.41	8,204.70
Net Profit / (Loss) from ordinary activities after tax, exceptional and extraordinary items	-1,431.55	1,792.07	3,312.35	5,878.53	8,204.70
Total Comprehensive Income for the period	-1,437.55	1,359.91	1,708.24	5,748.68	7,283.97
Equity Share Capital	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47
Other Equity				52,592.46	47,630.58
Earnings Per Share	-1.39	1.74	3.21	5,70	7.95
Basic and Diluted (in Rs.)	a property two cre				

Note: (1) The above is an extract of the detailed format of the Consolidated financial results for the Quarter and Year ended March 31, 2018 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. "

(2) The full format of the Standalone and Consolidated financial results for the Quarter and Year ended March 31, 2018 are available on the Stock Exchange websites- www.bseindia.com and www.nseindia.com and on the Company's website www.blissgvs.com.


(3) The results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act read with relevant rules issued there under.

(4) The Board of Directors in their meeting held on May 17, 2018 has recommended dividend of ₹1/- per equity share i.e., 100% for the financial year 2017-18 which is subject to approval of shareholders in Annual General Meeting.

For and on behalf of the Board of Directors SD/-

S. N. KAMATH MANAGING DIRECTOR

Place: Mumbai Date: 17th May'2018





## **BLISS GVS PHARMA LIMITED**

CIN No.- L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

### STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2018

Total Income ₹ 84167.50

PBT ₹ 14529.18 17.26%

EBITDA ₹ 18947.59 22.51%

**EPS** ₹ 5.70

. (₹ in Lakh

Particulars	CONSOLIDATED			CONSOLIDATED	
	QUARTER ENDED 31.03.2018 (AUDITED)	QUARTER ENDED 31.12.2017 (UN-AUDITED)	QUARTER ENDED 31.03.2017 (AUDITED)	YEAR ENDED 31.03.2018 (AUDITED)	YEAR ENDED 31.03.2017 (AUDITED)
Total income from operations (net)	16,710.04	19,592.25	25,838.09	81,514.00	80,235.11
Net Profit / (Loss) from ordinary activities after tax	1,988.33	1,792.07	3,312.35	9,298.41	8,204.70
Net Profit / (Loss) from ordinary activities after tax, exceptional and extraordinary items	-1,431.55	1,792.07	3,312.35	5,878.53	8,204.70
Total Comprehensive Income for the period	-1,437.55	1,359.91	1,708.24	5,748.68	7,283.97
Equity Share Capital	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47
Other Equity			dente minerale	52,592.46	47,630.58
Earnings Per Share	-1.39	1.74	3.21	5.70	7.95
Basic and Diluted (in Rs.)					

Note: (1) The above is an extract of the detailed format of the Consolidated financial results for the Quarter and Year ended March 31, 2018 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015."

(2) The full format of the Standalone and Consolidated financial results for the Quarter and Year ended March 31, 2018 are available on the Stock Exchange websites-www.bseindia.com and www.nseindia.com and on the Company's website www.blissgvs.com.

(3) The results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act read with relevant rules issued there under.

(4) The Board of Directors in their meeting held on May 17, 2018 has recommended dividend of ₹1/- per equity share i.e., 100% for the financial year 2017-18 which is subject to approval of shareholders in Annual General Meeting.

For and on behalf of the Board of Directors SD/-

S. N. KAMATH MANAGING DIRECTOR

Place : Mumbai Date : 17th May'2018





# BLISS GVS PHARMA LIMITED

CIN No.- L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2018

Total Income ₹ 84167.50

EBITDA ₹ 18947.59

PBT ₹ 14529.18

17.26%

**EPS** ₹ 5.70

					(₹ III Lakiis)
Particulars (mining and mining an	CONSOLIDATED			CONSOLIDATED	
	QUARTER ENDED 31.03.2018 (AUDITED)	QUARTER ENDED 31.12.2017 (UN-AUDITED)	QUARTER ENDED 31.03.2017 (AUDITED)	YEAR ENDED 31.03.2018 (AUDITED)	YEAR ENDED 31.03.2017 (AUDITED)
Total income from operations (net)	16,710.04	19,592.25	25,838.09	81,514.00	80,235.11
Net Profit / (Loss) from ordinary activities after tax	1,988.33	1,792.07	3,312.35	9,298.41	8,204.70
Net Profit / (Loss) from ordinary activities after tax, exceptional and extraordinary items	-1,431.55	1,792.07	3,312.35	5,878.53	8,204.70
Total Comprehensive Income for the period	-1,437.55	1,359.91	1,708.24	5,748.68	7,283.97
Equity Share Capital	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47
Other Equity	-			52,592.46	47,630.58
Earnings Per Share	-1.39	1.74	3.21	5.70	7.95
Basic and Diluted (in Rs.)		The state of the s	A CONTRACTOR OF THE PARTY OF TH	DISSESS HODE	2019 1 118/05/07/0

#### Note:

- (1) The above is an extract of the detailed format of the Consolidated financial results for the Quarter and Year ended March 31, 2018 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (2) The full format of the Standalone and Consolidated financial results for the Quarter and Year ended March 31, 2018 are available on the Stock Exchange websites-www.bseindia.com and www.nseindia.com and on the Company's website www.blissgvs.com.
- (3) The results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act read with relevant rules issued there under.
- (4) The Board of Directors in their meeting held on May 17, 2018 has recommended dividend of ₹ 1/- per equity share i.e., 100% for the financial year 2017-18 which is subject to approval of shareholders in Annual General Meeting.

For and on behalf of the Board of Directors SD/-

> S. N. KAMATH MANAGING DIRECTOR

Place: Mumbai Date: 17th May'2018